阿莫西林诱导的结晶性肾病:法国全国药物警戒数据库研究
该研究回顾性分析了法国国家药物警戒数据库和上市许可持有人药物警戒数据库中所有阿莫西林诱导的结晶性肾病(AICN)病例,共纳入101例。结果显示,AICN年报告率自2010年以来增加13倍,术后患者增加主要与不恰当给药有关,医疗患者增加始于2014年且多为老年心内膜炎患者。AICN是严重不良反应,评估 contributing factors 和在高剂量阿莫西林患者中开展药物监测可能降低风险。
要点
- AICN年报告率自2010年以来增加13倍,2010年前后分别为6和77例/10万患者年。
- 70例患者发生AKI KDIGO 3期,其中24例需肾脏替代治疗和/或ICU入住。
- 手术患者AICN增加主要与不恰当阿莫西林给药有关,医疗患者增加始于2014年。
核心结论
- AICN是严重药物不良反应,自2010年以来在法国急剧增加。
- 评估AICN contributing factors 和在高剂量阿莫西林患者中开展药物监测可能降低风险。
研究设计与样本
- 回顾性分析法国国家药物警戒数据库和上市许可持有人药物警戒数据库中所有AICN病例。
- 将AICN报告率与静脉阿莫西林及阿莫西林-克拉维酸销售量进行比较。
- 共纳入101例AICN病例。
主要发现
- 静脉阿莫西林/阿莫西林-克拉维酸用于手术预防32例,用于治疗感染69例。
- 70例患者发生AKI KDIGO 3期,其中24/70例需要肾脏替代治疗和/或ICU入住。
- AICN年报告率自2010年以来增加13倍(2010年前6[0;7]例/10万患者年,2010年后77[24;111]例/10万患者年,P < .001)。
- 手术患者AICN增加自2010年以来报告,主要与不恰当阿莫西林给药有关。
- 医疗患者AICN增加自2014年以来观察,2014年后医疗患者更老(67[42;77] vs 74岁[64;84],P < .05)且更常因心内膜炎治疗(0/20 vs 15/49,P < .01)。
临床怎么用
- 临床应关注阿莫西林尤其是高剂量静脉给药患者的AICN风险。
- 对接受高剂量阿莫西林的患者可考虑开展药物监测以降低AICN风险。
- 应评估AICN contributing factors,避免不恰当阿莫西林给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Amoxicillin (AMX)-induced crystal nephropathy (AICN) is a rarely reported adverse drug reaction (ADR) but its increase has been recently reported in the Paris area. Our aim was to investigate the incidence, characteristics and outcome of AICN in France. METHODS: Retrospective analysis of all AICN cases reported to the French National Pharmacovigilance Database and the Marketing Authorization Holders Pharmacovigilance Database. AICN notification rate was compared to intravenous AMX and AMX-clavulanate sales. RESULTS: In total, 101 AICN cases were included. Intravenous AMX/AMX-clavulanate was prescribed as surgical prophylaxis (32 surgical patients) or to treat infection (69 medical patients). AKI KDIGO stage 3 was observed in 70 patients and 24/70 patients required renal replacement therapy and/or intensive care unit admission. The annual notification rate of AICN was increased by a factor of 13 since 2010 (6 [0;7] and 77 [24;111] cases per 100 000 patient-years of exposure, before and after 2010 respectively; P < .001). In surgical patients, the increase in AICN has been reported since 2010 and was mainly related to inadequate AMX administration. In medical patients, the increase in AICN was observed since 2014. After 2014, medical patients were older (67 [42;77] vs 74 years [64;84] respectively; P < .05) and were treated more frequently for endocarditis (0/20 vs 15/49 respectively; P < .01). A contributing factor was observed or suspected in 62 patients. CONCLUSION: AICN is a severe ADR that dramatically increased in France since 2010. Assessment of AICN contributing factors and AMX drug monitoring in patients receiving high dose of AMX could reduce the risk of AICN.
引用
- Thomas L, Le Beller C, Trenque T, et al. Amoxicillin-induced crystal nephropathy: A nationwide French pharmacovigilance databases study. Br J Clin Pharmacol. 2020. PMID: 32353167. doi:10.1111/bcp.14328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。